CYP2D6 Inhibitors: Critical Precautions and Drug Interaction Management

Primary Drug Interaction Concerns

When prescribing CYP2D6 inhibitors like paroxetine and fluoxetine, avoid concurrent use with drugs that have narrow therapeutic indices metabolized by CYP2D6, particularly tamoxifen, tricyclic antidepressants, antiarrhythmics, and codeine, as these combinations can lead to treatment failure or serious toxicity 1, 2
Patients on tamoxifen should avoid paroxetine and fluoxetine whenever possible, and prescribers should select an alternative antidepressant with minimal or no CYP2D6 inhibition 1, 2, 3

CYP2D6 inhibitors block conversion of codeine to morphine, resulting in inadequate analgesia 4
Heightened vigilance is required postoperatively to avoid coadministration of CYP2D6 inhibitors with opioid prodrugs to ensure effective pain control 4

Avoid combining CYP2D6 inhibitors with other serotonergic agents, including triptans, tramadol, fentanyl, methadone, tapentadol, MAO inhibitors, SNRIs, and St. John's Wort, as this can increase the risk of serotonin syndrome 4
Serotonin syndrome is a potentially fatal toxicity state characterized by neuroexcitatory symptoms, autonomic dysfunction, and neuromuscular abnormalities 4

Before prescribing paroxetine or fluoxetine, review all current medications for CYP2D6 substrates, particularly those with narrow therapeutic indices, and consider alternative antidepressants for patients on tamoxifen 1, 2
If combination therapy is unavoidable, reduce doses of CYP2D6 substrate drugs by 50-75% and consider therapeutic drug monitoring for drugs with narrow therapeutic indices 3
Perioperative considerations include avoiding coadministration of CYP2D6 inhibitors with opioid prodrugs postoperatively and monitoring for inadequate analgesia if combination cannot be avoided 4